ALNYLAM PHARMACEUTICALS, INC. Payments for (Proceeds from) Tenant Allowance
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Payments for (Proceeds from) Tenant Allowance of -$5.55 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromTenantAllowance · last filed 2021-02-11
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for the quarter ending 2020-12-31 was -$2.86M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for the quarter ending 2020-09-30 was -$699.00K.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for the quarter ending 2020-06-30 was -$1.99M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for the quarter ending 2020-03-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for fiscal 2020 was -$5.55M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for fiscal 2019 was -$30.17M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for fiscal 2018 was -$25.35M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) tenant allowance for fiscal 2017 was $0.00.
| Period end | Payments for (Proceeds from) Tenant Allowance 3 month | Payments for (Proceeds from) Tenant Allowance 6 month | Payments for (Proceeds from) Tenant Allowance 9 month | Payments for (Proceeds from) Tenant Allowance 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$3.56M derived: sum of 2 quarters · filed 2021-02-11 | -$5.55M derived: sum of 3 quarters · filed 2021-02-11 | -$5.55M 10-K · filed 2021-02-11 |
| 2020-09-30 | -$699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$2.69M derived: sum of 2 quarters · filed 2020-11-05 | -$2.69M 10-Q · filed 2020-11-05 | -$3.80M derived: sum of 4 quarters · filed 2021-02-11 |
| 2020-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.99M 10-Q · filed 2020-08-06 | -$3.10M derived: sum of 3 quarters · filed 2021-02-11 | -$13.46M derived: sum of 4 quarters · filed 2021-02-11 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | -$1.11M derived: sum of 2 quarters · filed 2021-02-11 | -$11.47M derived: sum of 3 quarters · filed 2021-02-11 | -$17.78M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-12-31 | -$1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$11.47M derived: sum of 2 quarters · filed 2021-02-11 | -$17.78M derived: sum of 3 quarters · filed 2021-02-11 | -$30.17M 10-K · filed 2021-02-11 |
| 2019-09-30 | -$10.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$16.68M derived: sum of 2 quarters · filed 2020-11-05 | -$29.06M 10-Q · filed 2020-11-05 | -$42.82M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | -$6.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$18.70M 10-Q · filed 2020-08-06 | -$32.45M derived: sum of 3 quarters · filed 2021-02-11 | -$39.57M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | -$12.39M 10-Q · filed 2020-05-06 | -$26.14M derived: sum of 2 quarters · filed 2021-02-11 | -$33.26M derived: sum of 3 quarters · filed 2021-02-11 | |
| 2018-12-31 | -$13.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$20.87M derived: sum of 2 quarters · filed 2021-02-11 | -$25.35M 10-K · filed 2021-02-11 | |
| 2018-09-30 | -$7.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$11.60M 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | -$4.48M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | -$2.15M 10-K · filed 2019-02-14 | ||
| 2016-09-30 | -$2.15M 10-Q · filed 2017-11-07 | |||
| 2015-12-31 | -$374.00K 10-K · filed 2018-02-15 | |||
| 2014-12-31 | -$1.94M 10-K · filed 2017-02-15 | |||
| 2013-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$12.00K derived: sum of 2 quarters · filed 2016-02-12 | -$12.00K derived: sum of 3 quarters · filed 2016-02-12 | -$204.00K 10-K · filed 2016-02-12 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | -$192.00K 10-Q · filed 2014-11-06 | -$758.00K derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$192.00K 10-Q · filed 2014-08-08 | -$758.00K derived: sum of 3 quarters · filed 2015-02-13 | |
| 2013-03-31 | -$192.00K 10-Q · filed 2014-05-09 | -$758.00K derived: sum of 2 quarters · filed 2015-02-13 | ||
| 2012-12-31 | -$566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$1.78M 10-K · filed 2015-02-13 | ||
| 2012-09-30 | -$1.21M 10-Q · filed 2013-11-07 | |||
| 2008-12-31 | -$581.00K 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |